Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1987-2019Class II

C3 is an in vitro diagnostic assay for the quantitative determination of C3 in human serum or plasma...

Abbott Medical / initiated 2018-05-16 / Terminated / root cause: labeling and UDI

Abbott Laboratories, Inc began a recall of C3 is an in vitro diagnostic assay for the quantitative determination of C3 in human serum or plasma. Antibodies to C3 combine with C3 in the sample to form... on . FDA classified it as Class II and gives the reason as "An update to the Reagents and Specimen Collection and Handling/Preparation for Analysis sections of the IFU was required due to different issues with the various products". As of , the recall status on record is Terminated, and MDM tags the root cause as labeling and UDI.

Recall record

Recall number
Z-1987-2019
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Abbott Medical
Product
C3 is an in vitro diagnostic assay for the quantitative determination of C3 in human serum or plasma. Antibodies to C3 combine with C3 in the sample to form insoluble immune complexes. The immune complexes cause an increase in light scattering (turbidity). The resulting increase in sample turbidity, measured at 604 nm, is directly proportional to the concentration of C3 in the sample.
Product code
CZW Complement C3, Antigen, Antiserum, Control
Reason for recall
An update to the Reagents and Specimen Collection and Handling/Preparation for Analysis sections of the IFU was required due to different issues with the various products.
Root cause tag
labeling and UDI
FDA root cause
Under Investigation by firm
Action
The recalling firm issued letters dated 5/16/2019 via FedEx priority overnight express on 5/16/2019 to the U.S. customers. For OUS, each country organization needs to establish their own method of notification, which normally consists of mailings or customer visits.
Quantity in commerce
8,132 kits
Distribution
Distribution was nationwide, including Puerto Rico. There was government/military distribution. Foreign distribution was made to Canada, Albania, Algeria, Andorra, Argentina, Armenia, Australia, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Bolivia, Bosnia and Herzegovi, Botswana, Brazil, Brunei, Bulgaria, Chile, China, Costa Rica, Croatia, Curacao (Netherlands Antilles), Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Ecuador, Egypt, Estonia, Finland, France, Gaza & Jericho, Germany, Greece, Greenland, Honduras, Hong Kong, India, Iraq, Ireland, Israel, Italy, Ivory Coast, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Latvia, Lebanon, Libya. Lithuania, Luxembourg, Macedonia, Malaysia, Maldives, Mali, Mauritania, Mexico, Moldova, Montenegro, Morocco, Namibia, Netherlands, New Zealand, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Republic of Yemen, Romania, Russia, Rwanda, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad & Tobago, Tunisia, Turkey, Turks and Caicos, Tunisia, UAE, United Kingdom, Uruguay, and Viet Nam.
Product codes and lots
All IFU's

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1987-2019
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1987-2019Class IITerminatedVoluntary: Firm initiated
Z-1988-2019Class IITerminatedVoluntary: Firm initiated
Z-1989-2019Class IITerminatedVoluntary: Firm initiated
Z-1990-2019Class IITerminatedVoluntary: Firm initiated
Z-1991-2019Class IITerminatedVoluntary: Firm initiated
Z-1992-2019Class IITerminatedVoluntary: Firm initiated
Z-1993-2019Class IITerminatedVoluntary: Firm initiated
Z-1994-2019Class IITerminatedVoluntary: Firm initiated
Z-1995-2019Class IITerminatedVoluntary: Firm initiated